Tricuspid Valve

This channel is dedicated to news and trends in tricuspid valve interventions, surgical and transcatheter, to manage regurgitation and valve stenosis. The tricuspid valve is a rapidly growing area in structural heart interventions. Minimally invasive transcatheter tricuspid valve replacement (TTVR) and repair using transcatheter edge to edge repair (TEER) clips are expected to become a new standard of care in the next couple years, partly because open heart tricuspid surgery has historically has poor outcomes.

Heart failure biomarker identifies long-term risk in T-TEER patients
NT-proBNP measurements are often used to diagnose and manage heart failure. According to a new study of more than 2,000 patients, they can also provide value to cardiologists performing T-TEER.
Key trends in transcatheter tricuspid valve repair and replacement
The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.
TAVR, other interventional procedures may provide value for patients with carcinoid heart disease
These patients are typically treated with surgery, but those procedures carry their own risks that clinicians would prefer to avoid.
New technique could help when cardiologists repair 2 leaky heart valves at once
Performing M-TEER and T-TEER on the same patient using a single guide catheter appears to be both safe and effective. Researchers shared their experience with this approach in Circulation: Cardiovascular Interventions.
Evoque TTVR system linked to favorable outcomes in new real-world analysis
Researchers tracked data from more than 1,000 real-world patients, focusing on 30-day safety and efficacy outcomes. The group shared its findings at TCT 2025 in San Francisco.

Heart failure biomarker identifies long-term risk in T-TEER patients

NT-proBNP measurements are often used to diagnose and manage heart failure. According to a new study of more than 2,000 patients, they can also provide value to cardiologists performing T-TEER.

Transcatheter treatment of tricuspid valve disease has rapidly evolved over the past two years, giving physicians new tools to address a condition long considered under treated due to limited procedural options and complex anatomy. Ryan K. Kaple, MD, FACC, FSCAI, director of the structural and congenital heart program at Hackensack University Medical Center, spoke top Cardiovascular Business about recent advances and his center's real-world experience.

Key trends in transcatheter tricuspid valve repair and replacement

The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.

TAVR, other interventional procedures may provide value for patients with carcinoid heart disease

These patients are typically treated with surgery, but those procedures carry their own risks that clinicians would prefer to avoid.

An FDA panel will discuss its recommendations related to Abbott's TriClip G4 transcatheter edge-to-edge repair (TEER) system for tricuspid regurgitation.

New technique could help when cardiologists repair 2 leaky heart valves at once

Performing M-TEER and T-TEER on the same patient using a single guide catheter appears to be both safe and effective. Researchers shared their experience with this approach in Circulation: Cardiovascular Interventions.

Edwards Evoque transcatheter tricuspid valve replacement TTVR

Evoque TTVR system linked to favorable outcomes in new real-world analysis

Researchers tracked data from more than 1,000 real-world patients, focusing on 30-day safety and efficacy outcomes. The group shared its findings at TCT 2025 in San Francisco.

Cardiologists perform first TTVR of its kind on recent heart transplant recipient

When a 50-year-old patient developed severe TR just months after receiving a heart transplant, the safest treatment option was to implant an Evoque TTVR device.

American College of Cardiology shares new expert recommendations on treating tricuspid regurgitation

There have been so many developments in the treatment of TR that it can be challenging to keep up. The ACC crafted this new document to help ensure cardiologists, cardiac imagers and other clinicians have access to the most recent clinical data and policy decisions.

Edwards Lifesciences gains CE mark approval for Evoque transcatheter tricuspid valve replacement (TTVR) system

Old age, RBBB help predict when TTVR patients may require a permanent pacemaker

Though just a small, single-facility study, these findings help care teams know what to look for when performing transcatheter tricuspid valve replacement.